S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Official title

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Study identification

NCT ID

NCT01674140

Recruitment status

Active, not recruiting

Study type

Interventional

Phase

Phase 3

Lead sponsor

SWOG Cancer Research Network

Network

Enrollment

1,939 participants

Conditions and interventions

Eligibility (public fields only)

Age range

18 Years and older

Sex

All

Healthy volunteers

Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date

Sep 12, 2013 (Actual)

Primary completion

Dec 1, 2022 (Actual)

Completion

Jan 2030 (Estimated)

Last update posted

Feb 10, 2026

2013 – 2030

United States locations

U.S. sites

1455

U.S. states

51

U.S. cities

890